Aclaris Therapeutics, Inc.
ACRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001557746
No open-market purchases or sales by Aclaris Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $640.8M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +13 vs. previous quarter
- 148
- 13F valueReported value at the end of Q2 2026
- $640.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ACRS, Q2 2026
No superinvestor reported holding ACRS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Aclaris Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 (view filing) | Apr 23 | 4 days | Leonard Braden Michael10% Owner | SSale | −300.0K | $4.53 | −$1.36M | −2.1%13.9M after | |
| Nov 20, 2024 (view filing) | Nov 19 | 1 day | Mehra AnandDirector | PPurchase | +666.7K | $2.25 | +$1.50M | +1,537.4%710.0K after | |
| Aug 5, 2024 (view filing) | Aug 2-5 | 3 days | Leonard Braden Michael10% Owner | PPurchase | +373.6K | $1.26 | +$471.6K | +2.7%14.3M after | 2 lots |
| Jul 31, 2024 (view filing) | Jul 30-31 | 1 day | Leonard Braden Michael10% Owner | PPurchase | +273.7K | $1.31 | +$358.8K | +2.0%13.9M after | 2 lots |
| Jul 22, 2024 (view filing) | Jul 18-22 | 4 days | Leonard Braden Michael10% Owner | PPurchase | +154.7K | $1.30 | +$201.7K | +1.2%13.6M after | 3 lots |
| Jul 5, 2024 (view filing) | Jul 2-5 | 3 days | Leonard Braden Michael10% Owner | PPurchase | +352.4K | $1.15 | +$405.8K | +2.7%13.4M after | 3 lots |
| Jul 1, 2024 (view filing) | Jun 27-Jul 1 | 4 days | Leonard Braden Michael10% Owner | PPurchase | +1.54M | $1.13 | +$1.74M | +13.4%13.1M after | 4 lots |
| Jun 18, 2024 (view filing) | Jun 14-18 | 4 days | Leonard Braden Michael10% Owner | PPurchase | +545.0K | $1.16 | +$629.6K | +5.0%11.6M after | 3 lots |
| Jun 13, 2024 (view filing) | Jun 11-13 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +1.61M | $1.11 | +$1.78M | +17.1%11.0M after | 4 lots |
| Mar 5, 2024 (view filing) | Mar 1-4 | 4 days | Powell Andrew Kenneth WilliamDirector | PPurchase | +14.5K | $1.24 | +$18.0K | +101.0%28.9K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Aclaris Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 12,723,026 | $67.3M | 0.58% | +5,918,954+87.0% | Added |
| BML Capital Management, LLC | 11,975,000 | $63.3M | 36.18% | −2,275,000−16.0% | Reduced |
| BlackRock, Inc. | 10,037,008 | $53.1M | 0.00% | +2,629,943+35.5% | Added |
| Deep Track Capital, LP | 9,345,000 | $49.4M | 0.73% | 00.0% | Unchanged |
| Vivo Capital, LLC | 6,694,637 | $35.4M | 3.23% | +27,971+0.4% | Added |
| Vanguard Capital Management LLC | 5,817,866 | $30.8M | 0.00% | +650,397+12.6% | Added |
| Frazier Life Sciences Management, L.P. | 4,925,374 | $26.1M | 0.57% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 4,330,532 | $22.9M | 1.12% | −142,118−3.2% | Reduced |
| Adage Capital Partners GP, L.L.C. | 4,071,000 | $21.5M | 0.03% | +200,000+5.2% | Added |
| Decheng Capital LLC | 4,041,736 | $21.4M | 2.92% | 00.0% | Unchanged |